Pharmacokinetics of Intravenous Isavuconazole in Solid Organ Transplant Recipients.
In conclusion, moderate inter-patient variability in isavuconazole exposure, identification of factors associated with lower exposure, recognition that Ctrough is a surrogate marker for AUC and availability of a simple analytical method, suggest that therapeutic drug monitoring (TDM) may be useful for guiding treatment in at least some SOT recipients. Future studies are needed to correlate isavuconazole exposure with patients' clinical outcomes, and to determine the clinical role of TDM.
PMID: 30275091 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Wu X, Clancy CJ, Rivosecchi RM, Zhao W, Shields RK, Marini RV, Venkataramanan R, Nguyen MH Tags: Antimicrob Agents Chemother Source Type: research
More News: Aspergillus | Chemotherapy | Clinical Trials | Dialysis | Fungal Infections | Hemodialysis | Microbiology | Study | Transplants | Women